2015
Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature
Boga S, Jain D, Schilsky ML. Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature. BMC Pharmacology And Toxicology 2015, 16: 30. PMID: 26589720, PMCID: PMC4654910, DOI: 10.1186/s40360-015-0031-z.Peer-Reviewed Original ResearchConceptsSide effectsInduced colitisZinc therapyRare side effectYear old femaleLess side effectsAutosomal recessive disorderActive ileitisSevere pancolitisTrientine therapyImpaired excretionMucosal injuryInitial treatmentNeuropsychiatric symptomsSafety profileBrain accumulationBloody diarrheaCase reportRecent diagnosisTrientine treatmentChelation therapyTrientineColitisMedical treatmentWD symptoms
2009
Mycophenolate Mofetil-induced Colitis in Children
Phatak UP, Seo-Mayer P, Jain D, Selbst M, Husain S, Pashankar DS. Mycophenolate Mofetil-induced Colitis in Children. Journal Of Clinical Gastroenterology 2009, 43: 967-969. PMID: 19609219, DOI: 10.1097/mcg.0b013e3181a8754d.Peer-Reviewed Original ResearchConceptsMycophenolate mofetilSevere colitisMild gastrointestinal side effectsPediatric renal transplant patientsWithdrawal of MMFMaintenance of immunosuppressionRenal transplant patientsInflammatory bowel diseaseGastrointestinal side effectsCause of diarrheaMMF therapyHost diseaseTransplant patientsBowel diseaseColonic biopsiesHistologic featuresPatient 1Patient 2Histologic findingsComplete resolutionSide effectsColitisPatientsCausal associationMofetilHCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response